Skip to main
PLRX

PLRX Stock Forecast & Price Target

PLRX Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Pliant Therapeutics Inc. has established a solid scientific foundation for its competitive positioning in the growing biopharmaceutical sector, particularly with its lead candidate, bexotegrast (PLN-74809), which has shown positive results in clinical trials for treating idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis. The experienced management team demonstrates significant expertise in navigating regulatory processes, helping to mitigate potential risks associated with early-stage development and commercial execution. Additionally, the company's novel integrin-targeted delivery platform, along with an accelerated development plan for PLN-101095, indicates promising future growth potential and may unlock substantial value for stakeholders.

Bears say

Pliant Therapeutics Inc faces significant risks in the clinical development of its primary product candidate, bexotegrast, particularly due to historical failures associated with integrin inhibitors in treating idiopathic pulmonary fibrosis. The company is also exposed to regulatory uncertainties that could impact trial designs and outcomes, given the volatile nature of regulatory approvals faced by biotechnology firms. Additionally, a recent decrease in the company's cash position and share counts has raised concerns about its financial stability and ability to fund ongoing development efforts.

PLRX has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pliant Therapeutics (PLRX) Forecast

Analysts have given PLRX a Hold based on their latest research and market trends.

According to 3 analysts, PLRX has a Hold consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pliant Therapeutics (PLRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.